landiolol (Rapiblyk)
Jump to navigation
Jump to search
Indications
- atrial fibrillation with rapid ventricular response[1]
- atrial flutter
- tachyarrythmias
Dosage
- IV infusion
- bolus of 0.125 mg/kg to control heart rate during surgery
Pharmacokinetics
- rapidly metabolized in the plasma by pseudocholinesterases & carboxylesterases
* unlike esmolol, does not yield methanol
Adverse effects
- hypotension (10%) most common
- drug adverse effects of beta-adrenergic receptor antagonists
- drug adverse effects of beta-1 adrenergic receptor antagonists
- drug adverse effects of renin-angiotensin-aldosterone system inhibitors (RAAS inhibitors)
- drug adverse effects of antihypertensive agents
Mechanism of action
- ultra-short acting injectable betablocker
- does not increase renal sympathetic nerve activity
- does not increas plasma renin activity in patients anesthetized for surgery
More general terms
References
- ↑ 1.0 1.1 Domanovits H, Wolzt M, Stix G Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting. Eur Heart J Suppl. 2018 Jan 8;20(Suppl A):A1-A3 PMID: https://pubmed.ncbi.nlm.nih.gov/30188959 PMCID: PMC5909771
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION RAPIBLYK (landiolol) for injection, for intravenous use Initial U.S. Approval: 2024 https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217202s000lbl.pdf
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=114905
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=164457
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=636383
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6101892
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=163323281
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=89925388
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=163323282